Danny Tam

Prolonged and tunable residence time using reversible covalent kinase inhibitors

J. Michael Bradshaw, Jesse M. McFarland, Ville O. Paavilainen et al. · Nature Chemical Biology · 2015 · 430 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

Fawn Qian, Stefan Engst, Peiwen Yu et al. · Cancer Research · 2009 · 338 citations

Medicine, Oncology, Pharmacology +17

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

Patrick F. Smith, Janakan Krishnarajah, Philip A. Nunn et al. · British Journal of Clinical Pharmacology · 2017 · 102 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the Treatment of Solid Tumors

Ken A. Brameld, Timothy D. Owens, Erik Verner et al. · Journal of Medicinal Chemistry · 2017 · 96 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells

Michael P. Bova, Danny Tam, Gerald McMahon et al. · Toxicology Letters · 2004 · 79 citations

Life Sciences, Biochemistry, Pharmacology +13